Jiangsu Hengrui Pharmaceuticals: The Phase III clinical study of Darzalex HR for the adjuvant treatment of HR-positive breast cancer has reached its primary endpoint.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that in a recent multicenter, randomized, double-blind Phase III clinical trial, the company's independently developed hydroxyethyl sulfonate darzalex tablets combined with endocrine therapy for adjuvant treatment in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative female breast cancer, the first interim analysis of the primary endpoint reached statistical significance. The study results showed that darzalex combined with endocrine therapy significantly reduced the risk of recurrence in patients compared to placebo combined with endocrine therapy and improved patients' invasive disease-free survival (IDFS). The company has recently submitted an application for pre-communication with the Drug Evaluation Center of the National Medical Products Administration for marketing approval.